Ribonucleotide reductase is the rate limiting enzyme of deoxynucleoside triphosphate synthesis and is considered to be an excellent target of cancer chemotherapy. Trimidox, a newly synthesized compound, inhibits this enzyme and has in vitro and in vivo antitumour activity. As trimidox was able to upregulate the expression of the transferrin receptor in HL-60 human promyelocytic leukaemia cells, we have now investigated the capability of trimidox to interfere with iron metabolism. We show by photometric and polarographic methods that trimidox is able to form an iron complex. However, its cytotoxic action cannot be circumvented by addition of iron-saturated transferrin or iron-ammonium citrate, indicating that the iron complexing capacity is not responsible for the mechanism of action of this compound. When HL-60, K562 or L1210 leukaemia cells were incubated with the trimidoxiron complex itself, we could observe increases of the 50% growth inhibitory capacity of the complex in comparison with trimidox alone. We conclude that trimidox is able to form an iron complex, but in contrast to other agents, the anticancer activity cannot be contributed to this effect alone. Further studies will have to elucidate the molecular mechanism of action of this new and promising anticancer agent.
Introduction
Ribonucleotide reductase 1 ) is the rate limiting enzyme Investigators have synthesized a number of polyhyof de novo deoxyribonucleotide synthesis and shows an droxy-substituted benzohydroxamates as inhibitors of riincrease in activity linked with proliferation and malig-bonucleotide reductase (7, 8) . Among these compounds, nant transformation (1) (2) (3) . It was therefore considered trimidox (3,4,5-trihydroxybenzohydroxamidoxime) (fig. as a target for cancer chemotherapy (4) (5) (6) . A number 1) was most effective. It inhibited the growth of various of compounds inhibiting this enzyme were synthesized, tumour cell lines more effectively than hydroxyurea and Only hydroxyurea, a relatively weak inhibitor of ribonucleotide reduetase, is clinically used for the treatment of haematological malignancies. was demonstrated to have in vivo antitumour activity in L1210 leukaemia bearing mice (9, 10) . We could also show that trimidox yields synergistic cytotoxic effects with tiazoftirin, an inhibitor of IMP-dehydrogenase (11).
Trimidox was also able to upregulate the expression of differentiation linked surface markers and the expression of the transfenin receptor (CD 71) in HL-60 human promyelocytic leukaemia cells (11) . These results and previous reports suggested that iron chelation plays a role in the mechanism of trimidox action.
The aim of the present study was therefore to investigate whether trimidox is able to form complexes with iron salts and to elucidate the role of trimidox-iron intercalation regarding the biochemical and biological properties of this newly synthesized compound.
Materials and Methods

Chemicals arid supplies
Trimidox was synthesized as described (12) . All other chemicals and reagents were commercially available and of highest purity.
Cell culture
The HL-60 human promyelocytic cell line was a gift from Dr. R. C Gallo (National Cancer Institute, NIH, Bethesda, MD). K562 and LI210 leukaemia cell lines were purchased from ATCC (American Type Culture Collection, Rockville, MD, USA). Cells were grown in RPMI1640 medium supplemented with heat inactivated fetal calf serum (GIBCO, Grand Island Biological Co., Grand Island, NY, USA), volume fraction 0.1, supplemented with 1% penicillin-streptomycin in a humidified atmosphere containing 5% C0 2 . Cell counts were determined using the microcellcounter CC-108 (Sysmex, Kobe, Japan). Cells growing in logarithmic phase of growth were used for all studies described below. 
Growth inhibition assay
Cells were seeded in 25 cm 2 flasks at a cell density of 0.1 X 10 9 /1 and incubated with various drug concentrations (1-100 μπιοΐ/l). Cells were counted and IC 50 concentrations (drug concentration at 50% inhibition of cell growth) were determined 4 days later.
Polarographic measurements
Polarographic measurements were performed using a PA 4 po^· larographic analyzer, which was interfaced to a two-line XY 4106 plotter (Laboratorni Pristroje, Praha, The Czech Republic). A dropping mercury electrode with a drop time of 3 s and a flow rate of 2.27 mg/s at mercury column height h Hg of 81 cm was used as the indicating electrode. A saturated calomel electrode was used as the reference electrode. A platinum electrode was the auxiliary electrode. All polarographic measurements were carried out at room temperature in a stream of gaseous argon to exclude atmospheric oxygen from the polarographic cell. The pH was 7.02. 
Results
Formation of a trimidox-iron complex
Photometric determination
When trimidox (25-200 μτηοΐ/ΐ) was incubated with various concentrations of Fe-ammoniumcitrate (0-200 μπιοΐ/ΐ) in an aqueous solution, we could observe the formation of a violet colour complex. When 200 μηιοΙ/1 trimidox were incubated with 100 μπιοΐ/ΐ Fe-ammoniumcitrate in an aqueous solution for 2 hours at 37 °C, the photometric determination showed maximal absorption at 537 nm ( fig. 2, insert) .
The absorbance of the violet complex increased with increasing trimidox concentrations ( fig. 2, circles) , however when Fe-ammoniumcitrate was preincubated with 200 μιηοΐ/l desferroxamin for 1 hour prior to incubation with trimidox, the formation of the complex could be inhibited ( fig. 2, squares) . 
Discussion
Ribonucleotide reductase is the rate limiting enzyme of de novo deoxynucleoside triphosphate (dNTP) synthesis and was therefore considered to be an excellent target of cancer chemotherapy (1, 3, 5) . We have previously described the cytotoxic, differentiating and in vivo effects of a newly synthesized compond, trimidox (11) . We could show that trimidox inhibits ribonucleotide reductase activity and demonstrated that trimidox is able to upregulate transfenin receptor expression (CD 71) in human promyelocytic HL-60 cells (10, 11) . Combination of trimidox with tiazofurin, an : inhibitor of IMP dehydrogenase, caused synergistic cytotoxic and differentiation effects in HL-60 cells (11) . Our results indicate trimidox to be a promising agent for the treatment of human malignancies, however its mechanism of enzyme inhibition has not yet been elucidated (11) . The aim of the present study was to investigate whether the inhibit ion of the enzyme is caused by formation of an irontrimidox complex.
Ribonucleotide reductase consists of two distinct subunits (Rl, R2) which are required for enzymatic activity. Inhibition of the enzyme can be caused by scavenging of a free tyrosyl radical or iron deprivation, as iron is a cofactor for generation and stabilization of the free tyrosyl radical (5) . We could now clearly demonstrate and prove by photometric and polarographic determinations that trimidox is capable of forming a complex with iron. However addition of an iron salt to the culture medium did not significantly alter the growth inhibitory effect of trimidox in HL-60 cells, indicating that the iron binding property is not the main mechanism of action of the agent. We could also show that trimidox action was only slightly compromised by addition of iron-saturated transferrin.
When various cell lines were incubated with the irontrimidox complex itself, increases of the IC 50 s were observed when compared with the 50% growth inhibitory concentration of the pure compound in L1210 and K562 leukaemia cells. However, the cytotoxic effect of trimi- dox could not be circumvented completely as the IC 50 concentrations (14 and 16 μπιοΐ/ΐ in K562 and L1210 cells respectively) remained relatively low. Although trimidox is capable of forming a stable complex with iron, the mechanism of action of trimidox ought to be due to other chemical properties as well. It might be caused by the recently demonstrated free radical scavenging capacity of trimidox (13) or by other enzyme inhibitory effects. Further ongoing studies will have to elucidate the exact mechanism of action of this promising anticancer agent.
